JP2025000642A5 - - Google Patents

Download PDF

Info

Publication number
JP2025000642A5
JP2025000642A5 JP2024152809A JP2024152809A JP2025000642A5 JP 2025000642 A5 JP2025000642 A5 JP 2025000642A5 JP 2024152809 A JP2024152809 A JP 2024152809A JP 2024152809 A JP2024152809 A JP 2024152809A JP 2025000642 A5 JP2025000642 A5 JP 2025000642A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
binding fragment
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024152809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025000642A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/027650 external-priority patent/WO2017181021A1/en
Application filed filed Critical
Publication of JP2025000642A publication Critical patent/JP2025000642A/ja
Publication of JP2025000642A5 publication Critical patent/JP2025000642A5/ja
Pending legal-status Critical Current

Links

JP2024152809A 2016-04-15 2024-09-05 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療 Pending JP2025000642A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662323285P 2016-04-15 2016-04-15
US62/323,285 2016-04-15
US201762442802P 2017-01-05 2017-01-05
US62/442,802 2017-01-05
US201762450438P 2017-01-25 2017-01-25
US62/450,438 2017-01-25
US201762460428P 2017-02-17 2017-02-17
US62/460,428 2017-02-17
PCT/US2017/027650 WO2017181021A1 (en) 2016-04-15 2017-04-14 Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
JP2019505138A JP2019515027A (ja) 2016-04-15 2017-04-14 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療
JP2022108815A JP2022153418A (ja) 2016-04-15 2022-07-06 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022108815A Division JP2022153418A (ja) 2016-04-15 2022-07-06 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療

Publications (2)

Publication Number Publication Date
JP2025000642A JP2025000642A (ja) 2025-01-07
JP2025000642A5 true JP2025000642A5 (cg-RX-API-DMAC7.html) 2025-03-05

Family

ID=60041925

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019505138A Pending JP2019515027A (ja) 2016-04-15 2017-04-14 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療
JP2022108815A Pending JP2022153418A (ja) 2016-04-15 2022-07-06 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療
JP2024152809A Pending JP2025000642A (ja) 2016-04-15 2024-09-05 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019505138A Pending JP2019515027A (ja) 2016-04-15 2017-04-14 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療
JP2022108815A Pending JP2022153418A (ja) 2016-04-15 2022-07-06 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療

Country Status (9)

Country Link
US (3) US20190127455A1 (cg-RX-API-DMAC7.html)
EP (1) EP3442577A4 (cg-RX-API-DMAC7.html)
JP (3) JP2019515027A (cg-RX-API-DMAC7.html)
KR (2) KR20240005973A (cg-RX-API-DMAC7.html)
AU (2) AU2017250797A1 (cg-RX-API-DMAC7.html)
CA (1) CA3019665A1 (cg-RX-API-DMAC7.html)
IL (1) IL262277A (cg-RX-API-DMAC7.html)
SG (2) SG10202008378UA (cg-RX-API-DMAC7.html)
WO (1) WO2017181021A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
IL262207B2 (en) 2016-04-15 2026-01-01 Univ Pennsylvania Preparations for the treatment of wet age-related macular degeneration
CA3076905A1 (en) * 2017-09-27 2019-04-04 The Johns Hopkins University Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
CA3086045A1 (en) * 2017-12-19 2019-06-27 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
US12558434B2 (en) * 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
IL313246B2 (en) * 2018-06-28 2025-10-01 Univ North Carolina Chapel Hill Optimal cln5 expression genes and cassettes and their use
CN113853437A (zh) * 2018-11-07 2021-12-28 阿库斯股份有限公司 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途
EP4667578A3 (en) * 2019-04-03 2026-04-01 REGENXBIO Inc. Gene therapy for eye pathologies
US20220195462A1 (en) * 2019-04-24 2022-06-23 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
AU2020334924A1 (en) * 2019-08-22 2022-04-07 The Regents Of The University Of California UBE3A for the treatment of Angelman syndrome
CA3149401A1 (en) 2019-08-26 2021-03-04 Stephen Joseph Pakola Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab
WO2021071835A1 (en) 2019-10-07 2021-04-15 Regenxbio Inc. Adeno-associated virus vector pharmaceutical composition and methods
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113952474A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
EP4225381A1 (en) 2020-10-07 2023-08-16 RegenxBio Inc. Formulations for suprachoroidal administration such as formulations with aggregate formation
TW202228648A (zh) 2020-10-07 2022-08-01 美商銳進科斯生物股份有限公司 諸如高黏度調配物之用於脈絡膜上投與之調配物
JP2023544803A (ja) 2020-10-07 2023-10-25 レジェンクスバイオ インコーポレーテッド Cln2疾患の眼症状に対する遺伝子療法
TW202228646A (zh) 2020-10-07 2022-08-01 美商銳進科斯生物股份有限公司 諸如凝膠調配物之用於脈絡膜上投與之調配物
AU2021371307A1 (en) * 2020-10-28 2023-06-01 Regenxbio, Inc. VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
JP2024500115A (ja) * 2020-12-18 2024-01-04 エイシー イミューン ソシエテ アノニム 抗体デリバリー
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.
US20250026833A1 (en) * 2021-03-31 2025-01-23 WuXi Biologics Ireland Limited A bispecific anti-pd-l1/vegf antibody and uses thereof
US20260043046A1 (en) * 2022-03-17 2026-02-12 Adverum Biotechnologies, Inc. Cassettes of anti-complement component 3 antibody, vectorization and theraputic application
TW202404651A (zh) 2022-04-06 2024-02-01 美商銳進科斯生物股份有限公司 用於脈絡膜上投與之調配物諸如形成聚集體之調配物
TW202345913A (zh) 2022-04-06 2023-12-01 美商銳進科斯生物股份有限公司 用於脈絡膜上投與之調配物諸如凝膠調配物
AU2023250660A1 (en) 2022-04-06 2024-10-24 Regenxbio Inc. Pharmaceutical composition comprising a recombinant adenoassociated virus vector with an expression cassette encoding a transgene for suprachoroidal administration
EP4593955A1 (en) 2022-09-30 2025-08-06 RegenxBio Inc. Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388432A1 (en) * 1999-10-21 2001-04-26 Monsanto Company Post-translational modification of recombinant proteins produced in plants
US20020068694A1 (en) * 2000-07-26 2002-06-06 Jeltsch Markku Michael Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B
RU2567639C2 (ru) * 2009-06-17 2015-11-10 АббВай Биотерапеутикс Инк., Антитела против vegf и их применения
US20130090375A1 (en) * 2011-10-06 2013-04-11 Cornell University Virus-mediated delivery of bevacizumab for therapeutic applications
TWI698240B (zh) * 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
CR20160519A (es) * 2014-05-13 2017-01-27 The Trustees Of The Univ Of Pennysylvania Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos

Similar Documents

Publication Publication Date Title
JP2022153418A5 (cg-RX-API-DMAC7.html)
JP2022521851A5 (cg-RX-API-DMAC7.html)
JP2025121920A (ja) 完全ヒト翻訳後修飾抗体による治療剤
JP2021503914A5 (cg-RX-API-DMAC7.html)
JP2024016207A5 (cg-RX-API-DMAC7.html)
JP2022545967A5 (cg-RX-API-DMAC7.html)
CN117467025B (zh) 一种抗vegf和补体双功能融合蛋白及其应用
RU2018142768A (ru) Варианты капсидов аденоассоциированного вируса и способы их применения
JP2021516671A5 (cg-RX-API-DMAC7.html)
JP2022522776A5 (cg-RX-API-DMAC7.html)
JP2022523679A (ja) 体液性免疫を回避する組成物および方法
EP4549459A1 (en) Aav drug for treating angiogenesis-related fundus diseases
CN116444626A (zh) 经过修饰的aav衣壳蛋白及其用途
JP2024520815A5 (cg-RX-API-DMAC7.html)
JP2023547832A (ja) 眼の適応症に対するベクター化抗TNF-α抗体
US20240279324A1 (en) Multispecific antagonists
WO2023215806A2 (en) Vectorized anti-complement antibodies and complement agents and administration thereof
WO2022092326A1 (ja) 眼組織線維化の阻害に使用するためのgdf15調節物質
US20240269327A1 (en) Compositions and methods for transgene expression
CN121368636A (zh) 干性年龄相关性黄斑变性的治疗
TW202417633A (zh) 用於眼適應症之載體化抗TNF-α抑制劑
NZ746655B2 (en) Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
NZ746655A (en) Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
Chan Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting. Baltimore, Maryland, USA-May 7-11, 2017
WO2026107311A1 (en) Combination therapy for treatment of ocular disease